Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
InMed Pharmaceuticals Inc. shows decelerating business momentum based on AlphaOS pipeline evidence.
3 signals not yet derived from pipeline evidence
Pipeline evidence · 0d ago
INM's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on INM.
Free accounts see more of this; Premium sees all of it.
Reported figures for InMed Pharmaceuticals Inc. — research only, not investment advice.
Updated
What happened recently for InMed Pharmaceuticals Inc. (INM) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
INM's AI investment thesis
Upgrade to Premium for INM's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$1.38
Market cap
$7.58M
Profitable
No
Revenue $820,190.00
Net income
$-2.03M
FY Sep 1, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for InMed Pharmaceuticals Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow InMed Pharmaceuticals Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.